AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8846678
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glibenclamide
Trial: 27364603
Drug: COPD Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD Assessment Test (CAT) administered at baseline, 1.5 years, and 3 years.
Trial: 27364603
Drug: COPD Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD Assessment Test (CAT) administered to distinguish between exacerbation status.
Trial: 27364603
Drug: COPD Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD Assessment Test (CAT) administered to different demographic groups.
Trial: 20679551
Drug: Paramedic cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paramedic cooling with rapid infusion of 2 L of ice-cold lactated Ringer's solution
Trial: 16330196
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast for 4 weeks
Trial: 10937516
Drug: Dilazep dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep dihydrochloride (300 mg/day)
Trial: 3789755
Drug: Radiotherapy and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and/or combination chemotherapies (ACOP, ACOP‐E and AclBEP regimens)
Trial: 29304735
Drug: IV dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dexmedetomidine 0.5 μg.kg‐1 (Group DEX, n=30)
Trial: 18343242
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (30 mg nifedipine)
Trial: 18343242
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (30 mg nifedipine)
Trial: 9493517
Drug: Fixed-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months)
Trial: 9493517
Drug: Fixed-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months) in non-cirrhotic patients
Trial: 7982429
Drug: L-propionylcarnitine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionylcarnitine (1.5 g orally for 6 months)
Trial: 419810
Drug: Bencyclane 100
RxNorm normalized name: bencyclane 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencyclane 100 mg
Trial: 419810
Drug: Bencyclane 200
RxNorm normalized name: bencyclane 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencyclane 200 mg
Trial: 31669451
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VRE) combined with 50 mg D-Cycloserine (DCS)
Trial: 31669451
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure Therapy (PE) combined with 50 mg D-Cycloserine (DCS)
Trial: 31669451
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with Prolonged Exposure Therapy (PE)
Trial: 31669451
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with Virtual Reality Exposure Therapy (VRE)
Trial: 25586864
Drug: LNG/EE patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE patch (one patch weekly for three consecutive weeks, followed by a patch-free week for 13 cycles)
Trial: 25586864
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive for six cycles followed by seven LNG/EE patch cycles
Trial: 21372210
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg daily
Trial: 21372210
Drug: Atrasentan 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 1.75 mg daily
Trial: 21372210
Drug: Atrasentan 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.25 mg daily
Trial: 17278627
Drug: All 4
RxNorm normalized name: Flex-All 454
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 4 bonding agents
Trial: 15144613
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment group (group A)
Trial: 15144613
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment group (group B)
Trial: 11473503
Drug: Moclobemide (MCB)
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (MCB) 450-750 mg daily
Trial: 11473503
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine (IMI) 150-250 mg daily
Trial: 3191076
Drug: timolol administration
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: timolol administration to the normal eye
Trial: 28207733
Drug: Citalopram (SSRI)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (SSRI) administered for 2 weeks
Trial: 20008622
Drug: Imatinib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 800 mg/d
Trial: 21422420
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg/d plus interferon alfa (IFN-α)
Trial: 19794004
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy including WOSCOPS
Trial: 17068072
Drug: Alteplase 1
RxNorm normalized name: alteplase 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 1 mg/ml
Trial: 17068072
Drug: Alteplase or
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase or urokinase infusion
Trial: 15502051
Drug: Oxymorphone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone IR 30 mg
Trial: 15502051
Drug: Oxycodone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone IR 10 mg
Trial: 9702441
Drug: Amitriptyline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline plus sham treatment
Trial: 8045488
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha 2a 7.5 megaunits/m2 three times weekly for 6 mo (group 1)
Trial: 2729165
Drug: Zinc supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplement (10 mg Zn/d as ZnSO4)
Trial: 2729165
Drug: Control (boys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (boys with hair Zn greater than 1.68 mumol/g)
Trial: 18048461
Drug: Purified Vero
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Vero cell rabies vaccine (PVRV) given at 2, 4 months and 1 year
Trial: 18048461
Drug: Diphtheria, tetanus,
RxNorm normalized name: Diphtheria, Tetanus, Poliomyelitis adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria, tetanus, whole‐cell pertussis and inactivated poliomyelitis vaccine (DTP‐IPV)
Trial: 18048461
Drug: Purified Vero
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Vero cell rabies vaccine (PVRV) and DTP‐IPV
Trial: 16505510
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg twice a day for 12 weeks)
Trial: 14655024
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + methotrexate
Trial: 11389705
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (with corticosteroids)
Trial: 11389705
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (with corticosteroids and azathioprine)
Trial: 31719071
Drug: Perineural catheter
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural catheter (PNC) with continuous infusion of levobupivacaine hydrochloride 0.125% for up to 5 days
Trial: 29408444
Drug: l-arginine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (10 mM)
Trial: 27087145
Drug: Ivermectin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (30 mg oral, once a day)
Trial: 20622033
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren (PTC124) at lower dose (4, 4, and 8 mg/kg)
Trial: 20622033
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren (PTC124) at higher dose (10, 10, and 20 mg/kg)
Trial: 17558098
Drug: Tinospora cordifolia
RxNorm normalized name: tinospora cordifolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinospora cordifolia as an adjuvant therapy
Trial: 16623023
Drug: Sporal 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sporal 200 mg twice daily for 1 week
Trial: 16623023
Drug: Itracon 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itracon 200 mg twice daily for 1 week
Trial: 16623023
Drug: Itra 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itra 200 mg twice daily for 1 week
Trial: 8682088
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy plus conventional drug therapy for congestive heart failure
Trial: 1320131
Drug: CAV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV regimen (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 every 3 weeks)
Trial: 1320131
Drug: Menogaril (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menogaril (200 mg/m2 every 4 weeks)
Trial: 1320131
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy (etoposide 120 mg/m2 on days 1, 2, and 3 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Trial: 6325313
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (bovine fibrinolysin and desoxyribonuclease, no antibiotic)
Trial: 6325313
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (clostridiopeptidase and chloramphenicol)
Trial: 6325313
Drug: Preparation C
RxNorm normalized name: other nasal preparation combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation C (trypsin and framycetin sulphate)
Trial: 28948366
Drug: G/P (glecaprevir/pibrentasvir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 8 weeks
Trial: 28948366
Drug: OBV/PTV/r (ombitasvir/paritaprevir/ritonavir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBV/PTV/r (ombitasvir/paritaprevir/ritonavir) 25/150/100 mg for 12 weeks
Trial: 28948366
Drug: G/P (glecaprevir/pibrentasvir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 12 weeks
Trial: 23403419
Drug: Tigecycline 50
RxNorm normalized name: tigecycline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline 50 mg
Trial: 23403419
Drug: Tigecycline 200
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline 200 mg
Trial: 16750022
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg x m(‐2) YH‐16
Trial: 16750022
Drug: 15 mg/m(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/m(2) YH‐16
Trial: 14500805
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (40 microg subcutaneously daily)
Trial: 10768519
Drug: Amoxycillin/clavulanate 45/6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate 45/6.4 mg/kg/day twice-daily (b.d.)
Trial: 10768519
Drug: Amoxycillin/clavulanate 40/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate 40/10 mg/kg/day three-times-daily (t.d.s.)
Trial: 10768519
Drug: Amoxycillin/clavulanate twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate twice-daily (b.d.)
Trial: 10768519
Drug: Amoxycillin/clavulanate three-times-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate three-times-daily (t.d.s.)
Trial: 8620818
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral acyclovir (600-800 mg/day)
Trial: 8620818
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic therapy (group B)
Trial: 2666140
Drug: Cromakalim 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim 1 mg as a single daily oral dose for 5 days
Trial: 28032271
Drug: CBT-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-based treatment for Specific Phobias
Trial: 18292453
Drug: Prehydration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehydration with 10 mL/kg of lactated Ringer's solution
Trial: 8931648
Drug: Recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant growth hormone 0.05 IU/kg/d
Trial: 15902121
Drug: 200-microg buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-microg buccal misoprostol
Trial: 10489664
Drug: Tropisetron administration
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron administration before and 4 days after cisplatin treatment
Trial: 10489664
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration after tropisetron before cisplatin treatment
Trial: 9772614
Drug: Fumigation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumigation and inhalation of Huayin Powder
Trial: 1833088
Drug: GR32191B (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191B (80 mg orally before angioplasty and 80 mg/day orally for 6 months)
Trial: 1833088
Drug: Control (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (250 mg i.v. aspirin before angioplasty and placebo for 6 months)
Trial: 30147355
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone 150 mg/day
Trial: 30147355
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone (combined groups)
Trial: 22196510
Drug: Moxibustion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion therapy to CV4 and CV8 for 4 weeks (administered three times per week)
Trial: 18804894
Drug: Concomitant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm A.
Trial: 18804894
Drug: Concomitant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm B.
Trial: 29056859
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal system (BTDS) 5 μg/h titrated to 20 μg/h, once weekly for 6 weeks
Trial: 29056859
Drug: Oral tramadol/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol/acetaminophen (TA) 37.5 mg/325 mg, titrated to 4 tablets, twice daily for 6 weeks
Trial: 24023492
Drug: 4‐L PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐L PEG
Trial: 21129718
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment (atorvastatin 80 mg/day)
Trial: 21129718
Drug: Moderate-dose treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose treatment (atorvastatin 10 mg/day in TNT and simvastatin 20 to 40 mg/day in IDEAL)
Trial: 19920722
Drug: LidoDin cream
RxNorm normalized name: lidocaine hydrochloride Mucosal Spray [Lidodan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LidoDin cream
Trial: 11090260
Drug: Encapsulated algae-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated algae-derived DHA oil (0.57 g DHA/day) and fungal-derived AA oil (0.26 g AA/day) for 4 weeks
Trial: 8457236
Drug: Dried garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried garlic powder (Sapec) 900 mg
Trial: 30893271
Drug: CD101 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 3% gel applied intravaginally on days 1 and 2
Trial: 30893271
Drug: CD101 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 6% ointment applied intravaginally on day 1
Trial: 30893271
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 150 mg on day 1
Trial: 25118610
Drug: Magnesium carbonate
RxNorm normalized name: Magnesium Carbonate
DrugBank: Magnesium carbonate (DB09481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium carbonate plus calcium acetate as a phosphate binder (Mg group)
Trial: 25118610
Drug: Magnesium carbonate
RxNorm normalized name: Magnesium Carbonate
DrugBank: Magnesium carbonate (DB09481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium carbonate plus calcium acetate (Mg group)
Trial: 11999549
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone extract (61.8 mg of isoflavones)
Trial: 30576030
Drug: Loss of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loss of diagnosis (both treatments)
Trial: 25623883
Drug: Bitter melon
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter melon 2 g/day
Trial: 25623883
Drug: Bitter melon
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter melon 4 g/day
Trial: 17710804
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment, applied once daily for 30 minutes, with 2-3 courses on average
Trial: 17710804
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for liver protection
Trial: 6379505
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg/d
Trial: 11972164
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 mg
Trial: 11972164
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 mg
Trial: 11972164
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 mg
Trial: 11972164
Drug: Salmeterol 100
RxNorm normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 100 mg
Trial: 8602658
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at target concentrations of 0 ng/ml (Group A)
Trial: 8602658
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at target concentrations of 50 ng/ml (Group B)
Trial: 8602658
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at target concentrations of 200 ng/ml (Group C)
Trial: 8602658
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at target concentrations of 400 ng/ml (Group D)
Trial: 8602658
Drug: Alfentanil (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (0 to 500 ng/ml)
Trial: 1418778
Drug: Zidovudine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (250 mg every 6 h)
Trial: 1777174
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of zidovudine and acyclovir (800 mg every 6 h)
Trial: 27792047
Drug: Ropivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine plus dexmedetomidine (20 ml ropivacaine 0.5% plus 1 ml dexmedetomidine 100 µg/ml)
Trial: 27792047
Drug: Ropivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine plus placebo (20 ml ropivacaine 0.5% plus 1 ml saline)
Trial: 23413781
Drug: Amlodipine/valsartan (5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (5/160 mg once a day for 3 days) plus hydration (1 mL/kg/h sodium chloride infusion for 24 hours)
Trial: 23413781
Drug: Hydration only
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration only (1 mL/kg/h sodium chloride infusion for 24 hours)
Trial: 9620911
Drug: Inhaled recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled recombinant human IL-4